Literature DB >> 16177328

A DNA vaccine coding for the Brucella outer membrane protein 31 confers protection against B. melitensis and B. ovis infection by eliciting a specific cytotoxic response.

Juliana Cassataro1, Carlos A Velikovsky, Silvia de la Barrera, Silvia M Estein, Laura Bruno, Raúl Bowden, Karina A Pasquevich, Carlos A Fossati, Guillermo H Giambartolomei.   

Abstract

The development of an effective subunit vaccine against brucellosis is a research area of intense interest. The outer membrane proteins (Omps) of Brucella spp. have been extensively characterized as potential immunogenic and protective antigens. This study was conducted to evaluate the immunogenicity and protective efficacy of the B. melitensis Omp31 gene cloned in the pCI plasmid (pCIOmp31). Immunization of BALB/c mice with pCIOmp31 conferred protection against B. ovis and B. melitensis infection. Mice vaccinated with pCIOmp31 developed a very weak humoral response, and in vitro stimulation of their splenocytes with recombinant Omp31 did not induced the secretion of gamma interferon. Splenocytes from Omp31-vaccinated animals induced a specific cytotoxic-T-lymphocyte activity, which leads to the in vitro lysis of Brucella-infected macrophages. pCIOmp31 immunization elicited mainly CD8(+) T cells, which mediate cytotoxicity via perforins, but also CD4(+) T cells, which mediate lysis via the Fas-FasL pathway. In vivo depletion of T-cell subsets showed that the pCIOmp31-induced protection against Brucella infection is mediated predominantly by CD8(+) T cells, although CD4(+)T cells also contribute. Our results demonstrate that the Omp31 DNA vaccine induces cytotoxic responses that have the potential to contribute to protection against Brucella infection. The protective response could be related to the induction of CD8(+) T cells that eliminate Brucella-infected cells via the perforin pathway.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16177328      PMCID: PMC1230944          DOI: 10.1128/IAI.73.10.6537-6546.2005

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  60 in total

Review 1.  Cytotoxic T cells and mycobacteria.

Authors:  C L Silva; V L Bonato; K M Lima; A A Coelho-Castelo; L H Faccioli; A Sartori; A O De Souza; S C Leão
Journal:  FEMS Microbiol Lett       Date:  2001-04-01       Impact factor: 2.742

2.  Protective CTL response is induced in the absence of CD4+ T cells and IFN-gamma by gene gun DNA vaccination with a minigene encoding a CTL epitope of Listeria monocytogenes.

Authors:  A Yoshida; T Nagata; M Uchijima; Y Koide
Journal:  Vaccine       Date:  2001-07-20       Impact factor: 3.641

Review 3.  Molecular mechanisms of lymphocyte-mediated cytotoxicity and their role in immunological protection and pathogenesis in vivo.

Authors:  D Kägi; B Ledermann; K Bürki; R M Zinkernagel; H Hengartner
Journal:  Annu Rev Immunol       Date:  1996       Impact factor: 28.527

4.  Characterization of specific immune responses of mice inoculated with recombinant vaccinia virus expressing an 18-kilodalton outer membrane protein of Brucella abortus.

Authors:  R Vemulapalli; S Cravero; C L Calvert; T E Toth; N Sriranganathan; S M Boyle; O L Rossetti; G G Schurig
Journal:  Clin Diagn Lab Immunol       Date:  2000-01

5.  Plasmid DNA vaccines are effective in the absence of IFNgamma.

Authors:  D E Hassett; J Zhang; J L Whitton
Journal:  Virology       Date:  1999-10-10       Impact factor: 3.616

Review 6.  Immunity and protection against Brucella abortus.

Authors:  B Golding; D E Scott; O Scharf; L Y Huang; M Zaitseva; C Lapham; N Eller; H Golding
Journal:  Microbes Infect       Date:  2001-01       Impact factor: 2.700

7.  Disparate cytotoxic activity of nickel-specific CD8+ and CD4+ T cell subsets against keratinocytes.

Authors:  C Traidl; S Sebastiani; C Albanesi; H F Merk; P Puddu; G Girolomoni; A Cavani
Journal:  J Immunol       Date:  2000-09-15       Impact factor: 5.422

8.  Impaired control of Brucella melitensis infection in Rag1-deficient mice.

Authors:  M J Izadjoo; Y Polotsky; M G Mense; A K Bhattacharjee; C M Paranavitana; T L Hadfield; D L Hoover
Journal:  Infect Immun       Date:  2000-09       Impact factor: 3.441

9.  Identification of protective outer membrane antigens of Brucella ovis by passive immunization of mice with monoclonal antibodies.

Authors:  R A Bowden; S M Estein; M S Zygmunt; G Dubray; A Cloeckaert
Journal:  Microbes Infect       Date:  2000-04       Impact factor: 2.700

10.  Protection of BALB/c mice against Brucella abortus 544 challenge by vaccination with bacterioferritin or P39 recombinant proteins with CpG oligodeoxynucleotides as adjuvant.

Authors:  A Al-Mariri; A Tibor; P Mertens; X De Bolle; P Michel; J Godefroid; K Walravens; J J Letesson
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

View more
  34 in total

1.  Vaccination with the recombinant Brucella outer membrane protein 31 or a derived 27-amino-acid synthetic peptide elicits a CD4+ T helper 1 response that protects against Brucella melitensis infection.

Authors:  Juliana Cassataro; Silvia M Estein; Karina A Pasquevich; Carlos A Velikovsky; Silvia de la Barrera; Raúl Bowden; Carlos A Fossati; Guillermo H Giambartolomei
Journal:  Infect Immun       Date:  2005-12       Impact factor: 3.441

2.  Recombinant Lactococcus Lactis Displaying Omp31 Antigen of Brucella melitensis Can Induce an Immunogenic Response in BALB/c Mice.

Authors:  Hoda Shirdast; Fatemeh Ebrahimzadeh; Amir Hossein Taromchi; Yousef Mortazavi; Abdolreza Esmaeilzadeh; Mohammad Hadi Sekhavati; Keivan Nedaei; Esmat Mirabzadeh
Journal:  Probiotics Antimicrob Proteins       Date:  2021-02       Impact factor: 4.609

3.  Protective efficacy and safety of Brucella melitensis 16MΔmucR against intraperitoneal and aerosol challenge in BALB/c mice.

Authors:  A M Arenas-Gamboa; A C Rice-Ficht; M M Kahl-McDonagh; T A Ficht
Journal:  Infect Immun       Date:  2011-06-27       Impact factor: 3.441

4.  Construction of an expression plasmid (vector) encoding Brucella melitensis outer membrane protein, a candidate for DNA vaccine.

Authors:  Fatemeh Vahedi; Elnaz Ghorbani; Tahereh Falsafi
Journal:  Rep Biochem Mol Biol       Date:  2013-04

5.  Evaluation of the efficacy of outer membrane protein 31 vaccine formulations for protection against Brucella canis in BALB/c mice.

Authors:  Maria Clausse; Alejandra G Díaz; Andrés E Ibañez; Juliana Cassataro; Guillermo H Giambartolomei; Silvia M Estein
Journal:  Clin Vaccine Immunol       Date:  2014-10-22

6.  Partial protection against Brucella infection in mice by immunization with nonpathogenic alphaproteobacteria.

Authors:  M Victoria Delpino; Silvia M Estein; Carlos A Fossati; Pablo C Baldi
Journal:  Clin Vaccine Immunol       Date:  2007-08-22

7.  Protection of mice against Brucella abortus 544 challenge by vaccination with recombinant OMP28 adjuvanted with CpG oligonucleotides.

Authors:  Purushottam Kaushik; Dhirendra K Singh; S Vinoth Kumar; Ashok K Tiwari; Gunjan Shukla; Shanker Dayal; Pallav Chaudhuri
Journal:  Vet Res Commun       Date:  2009-12-16       Impact factor: 2.459

8.  Discordant Brucella melitensis antigens yield cognate CD8+ T cells in vivo.

Authors:  Marina A Durward; Jerome Harms; Diogo M Magnani; Linda Eskra; Gary A Splitter
Journal:  Infect Immun       Date:  2009-11-02       Impact factor: 3.441

9.  Coexpression of IL-18 strongly attenuates IL-12-induced systemic toxicity through a rapid induction of IL-10 without affecting its antitumor capacity.

Authors:  Maria Cecilia Rodriguez-Galan; Della Reynolds; Silvia G Correa; Pablo Iribarren; Morihiro Watanabe; Howard A Young
Journal:  J Immunol       Date:  2009-06-17       Impact factor: 5.422

10.  Evaluation of recombinant invasive, non-pathogenic Eschericia coli as a vaccine vector against the intracellular pathogen, Brucella.

Authors:  Jerome S Harms; Marina A Durward; Diogo M Magnani; Gary A Splitter
Journal:  J Immune Based Ther Vaccines       Date:  2009-01-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.